Management of persistent or recurrent medullary thyroid carcinoma

Problems in General Surgery

Volumn 14, Issue 4, 1997, Pages 89-110

  Musholt, Thomas J ^a,b   Moley, Jeffrey F ^a,c  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITONIN;

CALCITONIN BLOOD LEVEL; CANCER ADJUVANT THERAPY; CANCER LOCALIZATION; DIAGNOSTIC IMAGING; ECHOGRAPHY; HUMAN; LAPAROSCOPIC SURGERY; LIVER METASTASIS; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; METASTASIS; PATIENT SELECTION; PRIORITY JOURNAL; RECURRENT DISEASE; REOPERATION; REVIEW; SURGICAL TECHNIQUE; THYROID MEDULLARY CARCINOMA; VEIN CATHETERIZATION;

EID: 0031471743     PISSN: 07398328     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (128)

1. Russell CF, van Heerden JA, Sizemore GW, Edis AJ, Taylor WF, ReMine WH, Carney JA. The surgical management of medullary thyroid carcinoma. Ann Surg 1983;197:42-8.
2. Lips CJ, Landsvater RM, Hoppener JW, et al. Clinical screening as compared with DNA analysis in families with multiple endocrine neoplasia type 2A (comments). N Engl J Med 1994;331:828-35.
3. Wells SA Jr, Chi DD, Toshima K, et al. Predictive DNA testing and prophylactic thyroidectomy in patients at risk for multiple endocrine neoplasia type 2A (with discussion). Ann Surg 1994;220:237-50.
4. van Heerden JA, Grant CS, Gharib H, Hay ID, Ilstrup DM. Long-term course of patients with persistent hypercalcitoninemia after apparent curative primary surgery for medullary thyroid carcinoma (with discussion). Ann Surg 1990;212:395-401.
5. Brumsen C, Haak HR, Goslings BM, van de Velde CJ. Should patients with medullary thyroid carcinoma undergo extensive lymph node (re)operation to improve long-term survival? Henry Ford Hosp Med J 1992;40:271-5.
6. Tisell LE, Jansson S. Recent results of reoperative surgery in medullary carcinoma of the thyroid. Wien Klin Wochenschr 1988;100:347-8.
7. Moley JF, Wells SA Jr, Dilley WG, Tisell LE. Reoperation for recurrent or persistent medullary thyroid cancer (with discussion). Surgery 1993;114:1090-6.
8. Dralle H, Damm I, Scheumann GFW, Kotzerke J, Kupsch E, Geerlings H, Pichlmayr R. Compartment-oriented microdissection of regional lymph nodes in medullary thyroid carcinoma. Surg Today 1994;24:112-21.
9. Buhr HJ, Kallinowski F, Raue F, Frank-Raue K, Herfarth C. Microsurgical neck dissection for metastasizing medullary thyroid carcinoma. Eur J Surg Oncol 1995;21:195-7.
10. Eng C, Mulligan LM, Healey CS, et al. Heterogeneous mutation of the RET proto-oncogene in subpopulations of medullary thyroid carcinoma. Cancer Res 1996; 56:2167-70.
11. Bone HG III, Deftos LJ, Snyder WH, Pak CY. Mineral metabolic effects of thyroidectomy and long-term outcomes in a family with MEN 2A. Henry Ford Hosp Med J 1992;40:258-60.
12. Bracq S, Machairas M, Clement B, Pidoux E, Andreoletti M, Moukhtar MS, Jullienne A. Calcitonin gene expression in normal human liver. FEBS Lett 1993;331:15-8.
13. Ding YQ, Zhu LJ, Bagchi MK, Bagchi IC. Progesterone stimulates calcitonin gene expression in the uterus during implantation. Endocrinology 1994;135:2265-74.
14. Weber CJ, Kim D, Costanzo M, et al. Relationships of Na+ and K+ concentrations to GRP, CGRP, and calcitonin immunoreactivities and Na+,K(+)-ATPase (NKA) inhibitory activity in human breast cyst fluid. Ann Surg Oncol 1994;1:339-44.
15. Pilmane M, Luts A, Sundler F. Changes in neuroendocrine elements in bronchial mucosa in chronic lung disease in adults. Thorax 1995;50:551-4.
16. Nylen ES, Snider RH Jr, Thompson KA, Rohatgi P, Becker KL. Pneumonitis-associated hyperprocalcitoninemia. Am J Med Sci 1996;312:12-8.
17. Yocum MW, Butterfield JH, Gharib H. Increased plasma calcitonin levels in systemic mast cell disease. Mayo Clin Proc 1994;69:987-90.
18. Becker KL, Silva OL, Snider RH, Moore CF, Geelhoed GW. The surgical implications of hypercalcitoninemia. Surg Gynecol Obstet 1982;154:897-908.
19. Bugalho MJ, Roque L, Sobrinho LG, et al. Calcitonin-producing insulinoma: clinical, immunocytochemical and cytogenetical study. Clin Endocrinol (Oxf) 1994; 41:257-60.
20. Esik O, Nemeth G, Szepeshazi K. Calcitonin-secreting ovarian strumal carcinoid. Eur J Gynaecol Oncol 1994; 15:211-6.
21. McLeod MK, Vinik AI. Calcitonin immunoreactivity and hypercalcitoninemia in two patients with sporadic, nonfamilial, gastroenteropancreatic neuroendocrine tumors. Surgery 1992;111:484-8.
22. Kelley MJ, Snider RH Jr, Becker KL, Johnson BE. Small cell lung carcinoma cell lines express mRNA for calcitonin and alpha-and beta-calcitonin gene related peptides. Cancer Lett 1994;81:19-25.
23. di Sant'Agnese PA. Neuroendocrine differentiation in carcinoma of the prostate. Diagnostic, prognostic, and therapeutic implications. Cancer 1992;70:254-68.
24. Schaal JC, Lehmann M, Beller JP, Chabrier G, Rouyer N, Jaeck D. Ectopic calcitonin secretion by an adrenal metastasis of a mammary carcinoma (letter). Eur J Med 1992;1:444.
25. Gibson WG, Peng TC, Croker BP. Age-associated C-cell hyperplasia in the human thyroid. Am J Pathol 1982;106:388-93.
26. Wells SA Jr, Haagensen DE Jr, Linehan WM, Farrell RE, Dilley WG. The detection of elevated plasma levels of carcinoembryonic antigen in patients with suspected or established medullary thyroid carcinoma. Cancer 1978;42:1498-1503.
27. Busnardo B, Girelli ME, Simioni N, Nacamulli D, Busetto E. Nonparallel patterns of calcitonin and carcinoembryonic antigen levels in the follow-up of medullary thyroid carcinoma. Cancer 1984;53:278-285.
28. Cooper CW, Schwesinger WH, Mahgoub AM, Ontjes DA. Thyrocalcitonin: Stimulation of secretion by pentagastrin. Science 1971;172:1238-40.
29. Wells SA Jr, Baylin SB, Linehan WM, Farrell RE, Cox EB, Cooper CW. Provocative agents and the diagnosis of medullary carcinoma of the thyroid gland. Ann Surg 1978;188:139-41.
30. Motte P, Ait-Abdellah M, Vauzelle P, Gardet P, Bohuon C, Bellet D. A two-site immunoradiometric assay for serum calcitonin using monoclonal anti-peptide antibodies. Henry Ford Hosp Med J 1987;35:129-32.
31. Wimalawansa SJ, Bailey F. Validation, role in perioperative assessment, and clinical applications of an immunoradiometric assay for human calcitonin. Peptides 1995;16:307-12.
32. Guilloteau D, Perdrisot R, Calmettes C, et al. Diagnosis of medullary carcinoma of the thyroid (MCT) by calcitonin assay using monoclonal antibodies: Criteria for the pentagastrin stimulation test in hereditary MCT. J Clin Endocrinol Metab 1990;71:1064-7.
33. Body JJ, Heath H III. Estimates of circulating monomeric calcitonin: Physiological studies in normal and thyroidectomized man. J Clin Endocrinol Metab 1983;57:897-903.
34. Gautvik KM, Talle K, Hager B, Jorgensen OG, Aas M. Early liver metastases in patients with medullary carcinoma of the thyroid gland. Cancer 1989;63:175-80.
35. Weissel M, Kainz H, Tyl E, Ogunyemi E, Woloszczuk W. Clinical evaluation of new assays for determination of serum calcitonin concentrations. Acta Endocrinol 1991;124:540-4.
36. Tisell LE, Dilley WG, Wells SA Jr. Progression of postoperative residual medullary thyroid carcinoma as monitored by plasma calcitonin levels. Surgery 1996;119:34-9.
37. Girelli ME, Dotto S, Nacamulli D, et al. Prognostic value of early postoperative calcitonin level in medullary thyroid carcinoma. Tumori 1994;80:113-7.
38. Fugazzola L, Pinchera A, Luchetti F, et al. Disappearance rate of serum calcitonin after total thyroidectomy for medullary thyroid carcinoma. Int J Biol Markers 1994;9:21-4.
39. Kallinowski F, Buhr HJ, Meybier H, Eberhardt M, Herfarth C. Medullary carcinoma of the thyroid - therapeutic strategy derived from fifteen years of experience. Surgery 1993;114:491-6.
40. Moley JF, Dilley WG, DeBenedetti MK. Improved results of cervical reoperation for medullary thyroid carcinoma. Ann Surg 1997;225:734-43.
41. O'Riordain DS, O'Brien T, Weaver AL, Gharib H, Hay ID, Grant CS, van Heerden JA. Medullary thyroid carcinoma in multiple endocrine neoplasia types 2A and 2B. Surgery 1994;116:1017-23.
42. Bergholm U, Adami HO, Bergström R, Johansson H, Lundell G, Telenius-Berg M, Åkerström G. Clinical characteristics in sporadic and familial medullary thyroid carcinoma. A nationwide study of 249 patients in Sweden from 1959 through 1981. Cancer 1989; 63: 1196-204.
43. Stepanas AV, Samaan NA, Hill CS Jr, Hickey RC. Medullary thyroid carcinoma: Importance of serial serum calcitonin measurement. Cancer 1979;43:825-37.
44. Block MA, Jackson CE, Greenwald KA, Yott JB, Tashjian AH. Clinical characteristics distinguishing hereditary from sporadic medullary thyroid carcinoma. Arch Surg 1980;115:142-8.
45. Shah JP. Cervical lymph node metastases - diagnostic, therapeutic, and prognostic implications (with discussion). Oncology (Huntingt) 1990;4:61-9; 72, 76.
46. Ellenhorn JD, Shah JP, Brennan MF. Impact of therapeutic regional lymph node dissection for medullary carcinoma of the thyroid gland (with discussion). Surgery 1993;114:1078-82.
47. Dralle H, Damm I, Scheumann GF, Kotzerke J, Kupsch E. Frequency and significance of cervicomediastinal lymph node metastases in medullary thyroid carcinoma: Results of a compartment-oriented microdissection method. Henry Ford Hosp Med J 1992;40:264-7.
48. Buhr HJ, Kallinowski F, Raue F, Frank-Raue K, Herfarth C. Microsurgical neck dissection for occultly metastasizing medullary thyroid carcinoma. Three-year results. Cancer 1993;72:3685-93.
49. Musholt TJ, Scheumann GFW, Dralle H. Distant micrometastases - the clue to post-surgical hypercalcitoninemia in MTC (abstract). Eur J Surg Oncol 1994;20:287.
50. Dralle H, Scheumann GFW, Proye C, et al. The value of lymph node dissection in hereditary medullary thyroid carcinoma: A retrospective, European, multicentre study. J Intern Med 1995;238:357-61.
51. Raue F, Kotzerke J, Reinwein D, et al. Prognostic factors in medullary thyroid carcinoma: Evaluation of 741 patients from the German Medullary Thyroid Carcinoma Register. Clin Invest 1993;71:7-12.
52. Saad MF, Ordonez NG, Rashid RK, Guido JJ, Hill CS Jr, Hickey RC, Samaan NA. Medullary carcinoma of the thyroid. A study of the clinical features and prognostic factors in 161 patients. Medicine (Baltimore) 1984;63:319-42.
53. Rougier P, Parmentier C, Laplanche A, et al. Medullary thyroid carcinoma: Prognostic factors and treatment. Int J Radiat Oncol Biol Phys 1983;9:161-9.
54. Schröder S, Böcker W, Baisch H, et al. Prognostic factors in medullary thyroid carcinomas. Survival in relation to age, sex, stage, histology, immunocytochemistry, and DNA content. Cancer 1988;61:806-16.
55. Brierley J, Tsang R, Simpson WJ, Gospodarowicz M, Sutcliffe S, Panzarella T. Medullary thyroid cancer: Analysis of survival and prognostic factors and the role of radiation therapy in local control. Thyroid 1996; 6:305-10.
56. Norton JA, Froome LC, Farrell RE, Wells SA Jr. Multiple endocrine neoplasia type IIb: The most aggressive form of medullary thyroid carcinoma. Surg Clin North Am 1979;59:109-18.
57. O'Riordain DS, O'Brien T, Crotty TB, Gharib H, Grant CS, van Heerden JA. Multiple endocrine neoplasia type 2B: More than an endocrine disorder. Surgery 1995; 118:936-42.
58. Samaan NA, Schultz PN, Hickey RC. Medullary thyroid carcinoma: Prognosis of familial versus sporadic disease and the role of radiotherapy. J Clin Endocrinol Metab 1988;67:801-5.
59. Bergholm U, Adami HO, Bergström R, Backdahl M, Åkerström G. Long-term survival in sporadic and familial medullary thyroid carcinoma with special reference to clinical characteristics as prognostic factors. The Swedish MTC Study Group. Acta Chir Scand 1990;156:37-46.
60. Dottorini ME, Assi A, Sironi M, Sangalli G, Spreafico G, Colombo L. Multivariate analysis of patients with medullary thyroid carcinoma. Prognostic significance and impact on treatment of clinical and pathologic variables. Cancer 1996;77:1556-65.
61. Lippman SM, Mendelsohn G, Trump DL, Wells SA Jr, Baylin SB. The prognostic and biological significance of cellular heterogeneity in medullary thyroid carcinoma: A study of calcitonin, L-dopa decarboxylase, and histaminase. J Clin Endocrinol Metab 1982;54:233-40.
62. Pacini F, Elisei R, Anelli S, Basolo F, Cola A, Pinchera A. Somatostatin in medullary thyroid cancer. In vitro and in vivo studies. Cancer 1989;63:1189-95.
63. Grauer A, Schroth J, Ziegler R, Raue F. Evaluation of somatostatin as a plasma tumor marker in medullary thyroid carcinoma. Thyroid 1995;5:287-91.
64. Bergholm U, Adami HO, Auer G, et al. Histopathologic characteristics and nuclear DNA content as prognostic factors in medullary thyroid carcinoma. A nationwide study in Sweden. The Swedish MTC Study Group. Cancer 1989;64:135-12.
65. Ekman ET, Bergholm U, Backdahl M, Adami HO, Bergström R, Grimelius L, Auer G. Nuclear DNA content and survival in medullary thyroid carcinoma. Swedish Medullary Thyroid Cancer Study Group. Cancer 1990;65:511-7.
66. Pyke CM, Hay ID, Goellner JR, Bergstralh EJ, van Heerden JA, Grant CS. Prognostic significance of calcitonin immunoreactivity, amyloid staining, and flow cytometric DNA measurements in medullary thyroid carcinoma (comments; with discussion). Surgery 1991;110:964-71.
67. Mendelsohn G, Wells SA Jr, Baylin SB. Relationship of tissue carcinoembryonic antigen and calcitonin to tumor virulence in medullary thyroid carcinoma. An immunohistochemical study in early, localized, and virulent disseminated stages of disease. Cancer 1984; 54:657-62.
68. Saad MF, Ordonez NG, Guido JJ, Samaan NA. The prognostic value of calcitonin immunostaining in medullary carcinoma of the thyroid. J Clin Endocrinol Metab 1984;59:850-6.
69. Ruppert JM, Eggleston JC, deBustros A, Baylin SB. Disseminated calcitonin-poor medullary thyroid carcinoma in a patient with calcitonin-rich primary tumor. Am J Surg Pathol 1986;10:513-8.
70. Roncalli M, Viale G, Grimelius L, et al. Prognostic value of N-myc immunoreactivity in medullary thyroid carcinoma. Cancer 1994;74:134-41.
71. Schröder S, Schwarz W, Rehpenning W, Dralle H, Bay V, Böcker W. Leu-M1 immunoreactivity and prognosis in medullary carcinomas of the thyroid gland. J Cancer Res Clin Oncol 1988;114:291-6.
72. Längle F, Soliman T, Neuhold N, et al. CD15 (LeuM1) immunoreactivity: Prognostic factor for sporadic and hereditary medullary thyroid cancer? Study Group on Multiple Endocrine Neoplasia of Austria. World J Surg 1994;18:583-7.
73. Raue F, Winter J, Frank-Raue K, Lorenz D, Herfarth C, Ziegler R. Diagnostic procedure before reoperation in patients with medullary thyroid carcinoma. Horm Metab Res Suppl 1989;21:31-34.
74. Frank-Raue K, Raue F, Buhr HJ, Baldauf G, Lorenz D, Ziegler R. Localization of occult persisting medullary thyroid carcinoma before microsurgical reoperation: High sensitivity of selective venous catheterization. Thyroid 1992;2:113-7.
75. Dörr U, Würstlin S, Frank-Raue K, et al. Somatostatin receptor scintigraphy and magnetic resonance imaging in recurrent medullary thyroid carcinoma: A comparative study. Horm Metab Res Suppl 1993;27:48-55.
76. Reiners C. Imaging methods for medullary thyroid cancer (review). Recent Results Cancer Res 1992; 125:125-45.
77. Koizumi M, Taguchi H, Goto M, Nomura T, Watari T. Thallium-201 scintigraphy in the evaluation of thyroid nodules. A retrospective study of 246 cases. Ann Nucl Med 1993;7:147-52.
78. Ohnishi T, Noguchi S, Murakami N, Jinnouchi S, Hoshi H, Futami S, Watanabe K. Detection of recurrent thyroid cancer: MR versus thallium-201 scintigraphy. Am J Neuroradiol 1993;14:1051-7.
79. Bigsby RJ, Lepp EK, Litwin DE, Wilkinson AA, Matte GG. Technetium 99m pentavalent dimercaptosuccinic acid and thallium 201 in detecting recurrent medullary carcinoma of the thyroid. Can J Surg 1992;35:388-92.
80. Udelsman R, Ball D, Baylin SB, Wong CY, Osterman FA Jr, Sostre S. Preoperative localization of occult medullary carcinoma of the thyroid gland with single-photon emission tomography dimercaptosuccinic acid. Surgery 1993;114:1083-9.
81. Skowsky WR, Wilf LH. Iodine 131 metaiodobenzylguanidine scintigraphy of medullary carcinoma of the thyroid (published erratum appears in South Med J 1991;84:816,937) (review). South Med J 1991; 84:636-41.
82. Kwekkeboom DJ, Reubi JC, Lamberts SW, Bruining HA, Mulder AH, Oei HY, Krenning EP. In vivo somatostatin receptor imaging in medullary thyroid carcinoma. J Clin Endocrinol Metab 1993;76:1413-7.
83. Lebouthillier G, Morais J, Picard M, Picard D, Chartrand R, D'Amour P. Tc-99m sestamibi and other agents in the detection of metastatic medullary carcinoma of the thyroid. Clin Nucl Med 1993;18:657-61.
84. Krausz Y, Ish-Shalom S, Dejong RB, Shibley N, Lapidot M, Maaravi Y, Glaser B. Somatostatin-receptor imaging of medullary thyroid carcinoma. Clin Nucl Med 1994;19:416-21.
85. Dörr U, Sautter-Bihl ML, Bihl H. The contribution of somatostatin receptor scintigraphy to the diagnosis of recurrent medullary carcinoma of the thyroid. Semin Oncol 1994;21(suppl):42-5.
86. Baudin E, Lumbroso J, Schlumberger M, et al. Comparison of octreotide scintigraphy and conventional imaging in medullary thyroid carcinoma. J Nucl Med 1996;37:912-6.
87. Frank-Raue K, Bihl H, Dörr U, Buhr H, Ziegler R, Raue F. Somatostatin receptor imaging in persistent medullary thyroid carcinoma. Clin Endocrinol (Oxf) 1995;42:31-7.
88. 1/anti-indium-DTPA antibody and an indium-111-labeled DTPA dimer. J Nucl Med 1993;34:1267-73.
89. Parkkila S, Ahonen A, Tomiainen P, Heikkila J, Salmela P. Detection of cervical metastases of thyroid medullary carcinoma by MoAb anti-CEA scintigraphy and immunohistochemistry. Eur J Nucl Med 1995;22:1064-8.
90. Juweid M, Sharkey RM, Behr T, et al. Improved detection of medullary thyroid cancer with radiolabeled antibodies to carcinoembryonic antigen. J Clin Oncol 1996;14:1209-17.
91. Manil L, Boudet F, Motte P, et al. Positive anticalcitonin immunoscintigraphy in patients with medullary thyroid carcinoma. Cancer Res 1989;49:5480-5.
92. Waddington WA, Kettle AG, Heddle RM, Coakley AJ. Intraoperative localization of recurrent medullary carcinoma of the thyroid using indium-111 pentetreotide and a nuclear surgical probe. Eur J Nucl Med 1994; 21:363-4.
93. Tung WS, Vesely TM, Moley JF. Laparoscopic detection of hepatic metastases in patients with residual or recurrent medullary thyroid cancer (with discussion). Surgery 1995;118:1024-30.
94. Ben Mrad MD, Gardet P, Roche A, Rougier P, Calmettes C, Motte P, Parmentier C. Value of venous catheterization and calcitonin studies in the treatment and management of clinically inapparent medullary thyroid carcinoma. Cancer 1989;63:133-8.
95. Abdelmoumene N, Schlumberger M, Gardet P, Roche A, Travagli JP, Francese C, Parmentier C. Selective venous sampling catheterisation for localisation of persisting medullary thyroid carcinoma. Br J Cancer 1994;69:1141-4.
96. Norton JA, Doppman JL, Brennan MF. Localization and resection of clinically inapparent medullary carcinoma of the thyroid. Surgery 1980;87:616-22.
97. Pelizzo MR, Bernante P, Piotto A, et al. The extent of surgery for thyroid medullary cancer. Tumori 1994; 80:427-32.
98. Hazard JB, Hawk WA, Crile G. Medullary (solid) carcinoma of the thyroid - a clinicopathologic entity. J Clin Endocrinol Metab 1959;19:152-61.
99. Block MA, Jackson CE, Tashjian AH Jr. Management of occult medullary thyroid carcinoma: Evidenced only by serum calcitonin level elevations after apparently adequate neck operations. Arch Surg 1978;113:368-72.
100. Tisell LE, Hansson G, Jansson S, Salander H. Reoperation in the treatment of asymptomatic metastasizing medullary thyroid carcinoma. Surgery 1986;99:60-6.
101. Lamade W, Fogel W, Rieke K, Senninger N, Herfarth C. Intraoperative monitoring of the recurrent laryngeal nerve. A new method. Chirurg 1996;67: 451-1.
102. Tschopp K, Probst R. New aspects in surgery of the thyroid gland with intraoperative monitoring of the recurrent laryngeal nerve. Laryngorhinootologie 1994; 73:568-72.
103. Jansson S, Tisell LE. Autotransplantation of diseased parathyroid glands into subcutaneous abdominal adipose tissue. Surgery 1987;101:549-56.
104. Olson JA Jr, DeBenedetti MK, Baumann DS, Wells SA Jr. Parathyroid autotransplantation during thyroidectomy. Results of long-term follow-up (with discussion). Ann Surg 1996;223:472-80.
105. Dralle H, Scheumann GFW, Meyer HJ, Laubert A, Pichlmayr R. Cervical interventions on the airway and esophagus in infiltrating thyroid cancer. Chirurg 1992; 63:282-90.
106. Ballantyne AJ. Resections of the upper aerodigestive tract for locally invasive thyroid cancer. Am J Surg 1994;168:636-9.
107. Saad MF, Guido JJ, Samaan NA. Radioactive iodine in the treatment of medullary carcinoma of the thyroid. J Clin Endocrinol Metab 1983;57:124-8.
108. 131I-labeled monoclonal antibodies to carcinoembryonic antigen. Cancer Res 1995;55 (suppl): 5946S-51S.
109. Simpson WJ. Radiotherapy in thyroid cancer. Can Med Assoc J 1975;113:115-8.
110. Steinfeld AD. The role of radiation therapy in medullary carcinoma of the thyroid. Radiology 1977; 123:745-6.
111. Nguyen TD, Chassard JL, Lagarde P, et al. Results of postoperative radiation therapy in medullary carcinoma of the thyroid: A retrospective study by the French Federation of Cancer Institutes - the Radiotherapy Cooperative Group (review). Radiother Oncol 1992;23:1-5.
112. Yang KP, Liang YF, Samaan NA. Intrinsic drug resistance in a human medullary thyroid carcinoma cell line: Association with overexpression of mdrl gene and low proliferation fraction. Anticancer Res 1991;11:1065-8.
113. Gottlieb JA, Hill CS Jr. Chemotherapy of thyroid cancer with adriamycin. Experience with 30 patients. N Engl J Med 1974;290:193-7.
114. Husain M, Alsever RN, Lock JP, George WF, Katz FH. Failure of medullary carcinoma of the thyroid to respond to doxorubicin therapy. Horm Res 1978;9: 22-5.
115. Scherübl H, Raue F, Ziegler R. Combination chemotherapy of advanced medullary and differentiated thyroid cancer. Phase II study. J Cancer Res Clin Oncol 1990; 116:21-3.
116. Petursson SR. Metastatic medullary thyroid carcinoma. Complete response to combination chemotherapy with dacarbazine and 5-fluorouracil. Cancer 1988; 62:1899-903.
117. Orlandi F, Caraci P, Berruti A, Puligheddu B, Pivano G, Dogliotti L, Angeli A. Chemotherapy with dacarbazine and 5-fluorouracil in advanced medullary thyroid cancer. Ann Oncol 1994;5:763-5.
118. Schlumberger M, Abdelmoumene N, Delisle MJ, Couette JE. Treatment of advanced medullary thyroid cancer with an alternating combination of 5 FU-streptozocin and 5 FU-dacarbazine. The Groupe d'Etude des Tumeurs a Calcitonine (GETC). Br J Cancer 1995-71:363-5.
119. Wu LT, Averbuch SD, Ball DW, de Bustros A, Baylin SB, McGuire WP III. Treatment of advanced medullary thyroid carcinoma with a combination of cyclophosphamide, vincristine, and dacarbazine. Cancer 1994;73:432-6.
120. McCulloch P. Nonsurgical treatment of liver metastases. Curr Opin Gen Surg 1994:151-5.
121. Grohn P, Kumpulainen E, Jakobsson M. Response of medullary thyroid cancer to low-dose alpha-interferon therapy (letter). Acta Oncol 1990;29:950-1.
122. Lupoli G, Cascone E, Arlotta F, Vitale G, Celentano L, Salvatore M, Lombardi G. Treatment of Advanced Medullary Thyroid Carcinoma with a Combination of Recombinant Interferon α-2b and Octreotide. Cancer 1996;78:1114-8.
123. Trupp M, Arenas E, Fainzilber M, et al. Functional receptor for GDNF encoded by the c-ret proto-oncogene. Nature 1996;381:785-8.
124. Durbec P, Marcos-Gutierrez CV, Kilkenny C, et al. GDNF signalling through the Ret receptor tyrosine kinase. Nature 1996;381:789-93.
125. Jing S, Wen D, Yu Y, et al. GDNF-induced activation of the ret protein tyrosine kinase is mediated by GDNFR-alpha, a novel receptor for GDNF. Cell 1996;85:1113-24.
126. Treanor JJ, Goodman L, de Sauvage F, et al. Characterization of a multicomponent receptor for GDNF (comments). Nature 1996;382:80-3.
127. Ivanchuk SM, Myers SM, Eng C, Mulligan LM. De novo mutation of GDNF, ligand for the RET/GDNFR-alpha receptor complex, in Hirschsprung disease. Hum Mol Genet 1996;5:2023-6.
128. Moley JF. Medullary thyroid cancer. In: Clark OH, Duh Q-Y, eds. Textbook of Endocrine Surgery. Philadelphia: WB Saunders, 1997:108-118.